An AAV Platform Advancing Successful Viral Vector Based Therapeutics

By Michael Baker, PhD, Senior Director, Viral Gene Therapy

Decades of technological innovation and scientific advances have revolutionized the treatment paradigm for many conditions that have long eluded conventional therapies. Advanced viral vector-based therapeutic and immunization strategies, such as gene therapy, oncolytic viruses, and viral vaccines, are at the forefront of these innovative modalities and offer the promise of preventing or slowing the progression of, and perhaps even curing, previously unreachable conditions.

In this article, learn more about addressing substantial challenges in viral vector manufacture and an AAV platform approach that drives rapid and predictable progression of high-quality viral vector products from process development to clinical and commercial supply.